Table 3.
The trend change of monthly treatment price for within-class targeted anticancer drugs at launch and the latest (2022) between domestic and imported drugs.
| Characteristic | Initial monthly treatment price, median (IQR) | The latest treatment price, median (IQR) | Price reductiona |
|---|---|---|---|
| Domestic anticancer drugs | |||
| Breast cancer (CDK4/6 inhibitors) | 2843 (2843–2843) | 2843 (2843–2843) | 0% |
| Breast cancer (HER2-TKIs) | 4425 (4425–4425) | 1536 (1536–1536) | −65% |
| Breast cancer (HER2 mab inhibitors) | 2920 (2920–2920) | 1089 (1089–1089) | −63% |
| NSCLC (ALK inhibitors) | 5909 (5909–5909) | 1736 (1736–1736) | −71% |
| NSCLC (EGFR inhibitors) | 5235 (3817–6420) | 1075 (844–1337) | −79% |
| NSCLC (PD1/PDL1 inhibitors) | 4872 (4053–5408) | 878 (835–1397) | −81% |
| Hepatocellular carcinoma (PD1/PDL1 inhibitors) | 4663 (4544–6466) | 943 (788–1645) | −80% |
| Hepatocellular carcinoma (VEGFR inhibitors) | 3376 (3171–3581) | 1249 (1213–1286) | −63% |
| Colorectal cancer (VEGFR inhibitors) | 3785 (3785–3785) | 1222 (1222–1222) | −68% |
| Melanoma (PD1 inhibitors) | 2172 (2172–2172) | 543 (543–543) | −75% |
| Ovarian cancer (PAPR inhibitors) | 2897 (2741–3052) | 1439 (1439–1440) | −50% |
| Prostate cancer (AR inhibitors) | 3177 (3177–3177) | 3177 (3177–3177) | 0% |
| Imported anticancer drugs | |||
| Breast cancer (CDK4/6 inhibitors) | 4766 (4766–4766) | 2298 (2298–2298) | −52% |
| Breast cancer (HER2-TKIs) | 4637 (4350–4924) | 1270 (1139–1401) | −73% |
| Breast cancer (HER2-mab-inhibitors) | 7042 (7042–7042) | 1750 (1750–1750) | −75% |
| NSCLC (ALK inhibitors) | 4830 (3141–8614) | 2470 (2077–3141) | −49% |
| NSCLC (EGFR inhibitors) | 3049 (2853–3248) | 633 (528–739) | −79% |
| NSCLC (PD1/PDL1 inhibitors) | 8740 (8449–9031) | 7667 (7503–7831) | −12% |
| Hepatocellular carcinoma (PD1/PDL1 inhibitors) | 9875 (9875–9875) | 8972 (8972–8972) | −9% |
| Hepatocellular carcinoma (VEGFR inhibitors) | 5393 (5393–5393) | 2349 (2349–2349) | −56% |
| Colorectal cancer (VEGFR inhibitors) | 5393 (5393–5393) | 2349 (2349–2349) | −56% |
| Melanoma (PD1 inhibitors) | 8235 (8235–8235) | 7726 (7726–7726) | −6% |
| Ovarian cancer (PAPR inhibitors) | 10,138 (9342–10,934) | 1940 (1823–1996) | −81% |
| Prostate cancer (AR inhibitors) | 4923 (4264–5583) | 1068 (1033–1102) | −78% |
Prices are expressed in inflation-adjusted US dollars of monthly treatment.
AR, androgen receptor; PAPR, poly(ADP-ribose) polymerase; VEGFR, vascular endothelial growth factor receptor; TKIs, tyrosine kinase inhibitors; IQR, interquartile range.
a
Price reduction is defined as the percentage reduction in the monthly treatment price at the latest relative to the year at launch.